Now showing items 1-20 of 20

    • A case-control study of risk of leukaemia in relation to mobile phone use. 

      Cooke, R; Laing, S; Swerdlow, AJ (2010-11)
      Background Mobile phone use is now ubiquitous, and scientific reviews have recommended research into its relation to leukaemia risk, but no large studies have been conducted.Methods In a case-control study in South East ...
    • Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. 

      Rugo, HS; Lerebours, F; Ciruelos, E; Drullinsky, P; Ruiz-Borrego, M; Neven, P; Park, YH; Prat, A; Bachelot, T; Juric, D; Turner, N; Sophos, N; Zarate, JP; Arce, C; Shen, Y-M; Turner, S; Kanakamedala, H; Hsu, W-C; Chia, S
      Background Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in ...
    • Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. 

      Premenopausal Breast Cancer Collaborative Group; Schoemaker, MJ; Nichols, HB; Wright, LB; Brook, MN; Jones, ME; O'Brien, KM; Adami, H-O; Baglietto, L; Bernstein, L; Bertrand, KA; Boutron-Ruault, M-C; Braaten, T; Chen, Y; Connor, AE; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Hankinson, SE; Kaaks, R; Key, TJ; Kirsh, VA; Kitahara, CM; Koh, W-P; Larsson, SC; Linet, MS; Ma, H; Masala, G; Merritt, MA; Milne, RL; Overvad, K; Ozasa, K; Palmer, JR; Peeters, PH; Riboli, E; Rohan, TE; Sadakane, A; Sund, M; Tamimi, RM; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Willett, WC; Wolk, A; Yuan, J-M; Zeleniuch-Jacquotte, A; Sandler, DP; Swerdlow, AJ (2018-11-08)
      Importance The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover ...
    • Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. 

      Nichols, HB; Schoemaker, MJ; Cai, J; Xu, J; Wright, LB; Brook, MN; Jones, ME; Adami, H-O; Baglietto, L; Bertrand, KA; Blot, WJ; Boutron-Ruault, M-C; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Hoffman-Bolton, J; Kaaks, R; Key, TJ; Kitahara, CM; Larsson, SC; Linet, M; Merritt, MA; Milne, RL; Pala, V; Palmer, JR; Peeters, PH; Riboli, E; Sund, M; Tamimi, RM; Tjønneland, A; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Wolk, A; Zheng, W; Weinberg, CR; Swerdlow, AJ; Sandler, DP (2019-01)
      Background Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or ...
    • Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study. 

      Swerdlow, AJ; Cooke, R; Beckers, D; Borgström, B; Butler, G; Carel, J-C; Cianfarani, S; Clayton, P; Coste, J; Deodati, A; Ecosse, E; Gausche, R; Giacomozzi, C; Hokken-Koelega, ACS; Khan, AJ; Kiess, W; Kuehni, CE; Mullis, P-E; Pfaffle, R; Sävendahl, L; Sommer, G; Thomas, M; Tidblad, A; Tollerfield, S; Van Eycken, L; Zandwijken, GRJ (2017-05)
      Context Growth hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited.Objective To examine cancer risks in relation to GH ...
    • Circulating Growth and Sex Hormone Levels and Breast Tissue Composition in Young Nulliparous Women. 

      Denholm, R; De Stavola, BL; Hipwell, JH; Doran, SJ; Holly, JMP; Folkerd, E; Dowsett, M; Leach, MO; Hawkes, DJ; Dos-Santos-Silva, I (2018-12)
      Background Endogenous hormones are associated with breast cancer risk, but little is known about their role on breast tissue composition, a strong risk predictor. This study aims to investigate the relationship between ...
    • Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification. 

      Pal Choudhury, P; Wilcox, AN; Brook, MN; Zhang, Y; Ahearn, T; Orr, N; Coulson, P; Schoemaker, MJ; Jones, ME; Gail, MH; Swerdlow, AJ; Chatterjee, N; Garcia-Closas, M (2020-03)
      Background External validation of risk models is critical for risk-stratified breast cancer prevention. We used the Individualized Coherent Absolute Risk Estimation (iCARE) as a flexible tool for risk model development and ...
    • CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites. 

      Sood, D; Johnson, N; Jain, P; Siskos, AP; Bennett, M; Gilham, C; Busana, MC; Peto, J; Dos-Santos-Silva, I; Keun, HC; Fletcher, O (2017-01-10)
      Background Endogenous sex hormones are well-established risk factors for breast cancer; the contribution of specific oestrogen metabolites (EMs) and/or ratios of specific EMs is less clear. We have previously identified a ...
    • De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome. 

      Jansen, S; Geuer, S; Pfundt, R; Brough, R; Ghongane, P; Herkert, JC; Marco, EJ; Willemsen, MH; Kleefstra, T; Hannibal, M; Shieh, JT; Lynch, SA; Flinter, F; FitzPatrick, DR; Gardham, A; Bernhard, B; Ragge, N; Newbury-Ecob, R; Bernier, R; Kvarnung, M; Magnusson, EAH; Wessels, MW; van Slegtenhorst, MA; Monaghan, KG; de Vries, P; Veltman, JA; Deciphering Developmental Disorders Study; Lord, CJ; Vissers, LELM; de Vries, BBA (2017-04)
      Intellectual disability (ID) is a highly heterogeneous disorder involving at least 600 genes, yet a genetic diagnosis remains elusive in ∼35%-40% of individuals with moderate to severe ID. Recent meta-analyses statistically ...
    • Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study. 

      Johns, LE; Jones, ME; Schoemaker, MJ; McFadden, E; Ashworth, A; Swerdlow, AJ (2018-02)
      BACKGROUND:Circadian disruption caused by exposure to light at night (LAN) has been proposed as a risk factor for breast cancer and a reason for secular increases in incidence. Studies to date have largely been ecological ...
    • Familial gigantism caused by an NSD1 mutation. 

      van Haelst, MM; Hoogeboom, JJM; Baujat, G; Brüggenwirth, HT; Van de Laar, I; Coleman, K; Rahman, N; Niermeijer, MF; Drop, SLS; Scambler, PJ (2005-11)
      A three-generation family with autosomal dominant segregation of a novel NSD1 mutation (6605G --> A, resulting in Cys2202Tyr) is reported. Haploinsufficiency of NSD1 has been identified as the major cause of Sotos syndrome. ...
    • Family history and risk of breast cancer: an analysis accounting for family structure. 

      Brewer, HR; Jones, ME; Schoemaker, MJ; Ashworth, A; Swerdlow, AJ (2017-08)
      Purpose Family history is an important risk factor for breast cancer incidence, but the parameters conventionally used to categorize it are based solely on numbers and/or ages of breast cancer cases in the family and take ...
    • Mortality and Cancer Incidence in Carriers of Balanced Robertsonian Translocations: A National Cohort Study. 

      Schoemaker, MJ; Jones, ME; Higgins, CD; Wright, AF; United Kingdom Clinical Cytogenetics Group; Swerdlow, AJ (2019-03)
      A balanced robertsonian translocation (rob) results from fusion of 2 acrocentric chromosomes. Carriers are phenotypically normal and are often diagnosed because of recurrent miscarriages, infertility, or aneuploid offspring. ...
    • Mortality and cancer incidence in carriers of constitutional t(11;22)(q23;q11) translocations: A prospective study. 

      Schoemaker, MJ; Jones, ME; Higgins, CD; Wright, AF; UK Clinical Cytogenetics Group; Swerdlow, AJ (2019-09)
      The constitutional t(11;22)(q23;q11) translocation is the only recurrent non-Robertsonian translocation known in humans. Carriers are phenotypically normal and are usually referred for cytogenetic testing because of multiple ...
    • Mortality and cancer incidence in persons with Down's syndrome, their parents and siblings. 

      Hermon, C; Alberman, E; Beral, V; Swerdlow, AJ (2001-03)
      A cohort study of 1425 persons with Down's syndrome (DS), and of their parents (447 mothers, 435 fathers) and siblings (1176), was set up to investigate death rates from various causes and cancer incidence patterns. In ...
    • Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: a cohort study. 

      Swerdlow, AJ; Hermon, C; Jacobs, PA; Alberman, E; Beral, V; Daker, M; Fordyce, A; Youings, S (2001-03)
      Mortality and cancer incidence were assessed in a cohort of 1373 patients with numerical sex chromosome abnormalities diagnosed at three cytogenetics centres in Britain during 1959-90, and were compared with expectations ...
    • Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability. 

      Tatton-Brown, K; Loveday, C; Yost, S; Clarke, M; Ramsay, E; Zachariou, A; Elliott, A; Wylie, H; Ardissone, A; Rittinger, O; Stewart, F; Temple, IK; Cole, T; Childhood Overgrowth Collaboration; Mahamdallie, S; Seal, S; Ruark, E; Rahman, N (2017-05)
      To explore the genetic architecture of human overgrowth syndromes and human growth control, we performed experimental and bioinformatic analyses of 710 individuals with overgrowth (height and/or head circumference ≥+2 SD) ...
    • Paracrine-stimulated gene expression profile favors estradiol production in breast tumors. 

      Amin, SA; Huang, C-C; Reierstad, S; Lin, Z; Arbieva, Z; Wiley, E; Saborian, H; Haynes, B; Cotterill, H; Dowsett, M; Bulun, SE (2006-07)
      Paracrine interactions between adipose fibroblasts and malignant epithelial cells are essential for structural and hormonal support of breast tumors. Factors derived from malignant epithelial cells inhibit adipogenic ...
    • Risk of Meningioma in European Patients Treated With Growth Hormone in Childhood: Results From the SAGhE Cohort. 

      Swerdlow, AJ; Cooke, R; Beckers, D; Butler, G; Carel, J-C; Cianfarani, S; Clayton, P; Coste, J; Deodati, A; Ecosse, E; Hokken-Koelega, ACS; Khan, AJ; Kiess, W; Kuehni, CE; Flück, CE; Pfaffle, R; Sävendahl, L; Sommer, G; Thomas, M; Tidblad, A; Tollerfield, S; Zandwijken, GRJ (2019-03)
      Context:There has been concern that GH treatment of children might increase meningioma risk. Results of published studies have been inconsistent and limited. Objective:To examine meningioma risks in relation to GH treatment. ...
    • Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study. 

      Bodicoat, DH; Schoemaker, MJ; Jones, ME; McFadden, E; Griffin, J; Ashworth, A; Swerdlow, AJ (2014-02-04)
      Introduction Breast development and hormonal changes at puberty might affect breast cancer risk, but epidemiological analyses have focussed largely on age at menarche and not at other pubertal stages.Methods We investigated ...